现任领导

马骏

职务：中心常务副主任、常务副院长

马骏，中国科学院院士，中山大学肿瘤防治中心常务副主任、医院常务副院长，教授，博士生导师。

担任国务院学位委员会特种医学学科评议组召集人、第八届教育部科学技术委员会生命医学部委员、中山大学学术委员会主任委员、中华医学会放射肿瘤治疗分会候任主任委员、中国临床肿瘤学会(CSCO)鼻咽癌专业委员会主任委员、中国抗癌协会(CACA)鼻咽癌专业委员会主任委员、国际鼻咽癌Gordon大会候任主席、美国 AJCC 鼻咽癌临床分期委员会核心成员，美国ASCO科学审查委员会成员、ESCO头颈部肿瘤科学委员会委员等。

马骏教授是具有重要国际影响力的鼻咽癌诊治专家。40年来，他针对全身微小转移灶是引起鼻咽癌转移复发的根源，开展清除与甄别全身微小转移灶的系列研究，提出了吉西他滨联合顺铂（GP）全身化学治疗（化疗）可重塑以B细胞为核心的抗肿瘤免疫，有效清除全身微小转移灶的增效理论，制定了先GP全身化疗，后局部放射治疗（放疗）及结合PD-1单抗的新策略，大幅提高了晚期鼻咽癌患者的生存率；同时，马骏采用临床分期联合mRNA分子标签甄别极少发生微小转移灶的低危患者、绘制鼻咽癌演进图谱识别低危受累的鼻咽及淋巴结区域，提出了基于风险高低降低治疗强度的减毒理论，制定了豁免同期化疗及缩小放疗范围的新方案，显著减少放化疗的毒副反应，改善了生活质量。

马骏以共同/唯一通讯作者发表190余篇，总他引10150次，包括国际医学顶尖刊物CA Cancer J Clin、N Engl J Med、Lancet（3篇）、JAMA（2篇）、BMJ（2篇）、Nat Med、Cancer Cell（2篇）、Lancet Oncol（7篇）、J Clin Oncol（2篇）、Ann Oncol（2篇），共19篇入选 ESI 1%高被引论文，3篇入选1‰热点论文。1998年至今，鼻咽癌美国指南中诊疗路径和美国癌症联合会/国际抗癌联盟（AJCC/UICC）临床分期标准分别进行了6项和15项重大调整，其中5项和9项是基于马骏的研究成果。

受美国临床肿瘤协会（ASCO）邀请，马骏作为主席牵头制定了《中国-美国临床肿瘤学会鼻咽癌临床诊治国际指南》（J Clin Oncol 2021，高被引），还牵头制定了《中国-美国-欧洲鼻咽癌原发灶/颈部靶区勾画及图谱》（Lancet Oncol 2篇 2025），指导了全球临床实践；他还受邀为《Lancet》撰写Seminar（Lancet 2019，热点论文）, 向全球医生介绍鼻咽癌的诊疗规范及进展。马骏作为第一完成人获得3项国家科技进步二等奖，荣获何梁何利基金科学与技术进步奖、吴阶平医药创新奖、谈家桢临床医学奖等，成果入选中国科协中国生命科学十大进展3项、中国高等学校十大科技进展及中国医学科学院中国医学重大进展各2项。

马骏教授是国家外专局/教育部“创新引智基地（111计划）”项目负责人，作为大会主席连续主办8届（2018~2024年）国际头颈肿瘤研讨会，应邀在国外肿瘤学大会做报告20次。他受邀主编首部英文专著《Nasopharyngeal Cancer - A Practical Guide on Diagnosis and Treatment》（Springer出版，2021），15项研究结果写入了世界通用的放射治疗权威教科书。他指导的研究生获得国家高层次人才称号8人次，率领团队先后获评“科技部重点领域创新团队”及“教育部创新团队”。中山大学肿瘤医院是世界最大的鼻咽癌治疗中心，在欧洲机构“Expertscape”全球鼻咽癌学术排名中名列第一，马骏为此做出了重要科学贡献。

分管教学（含招生）、预防医学工作。分管部门：科教处（教学与研究生科、毕业后与继续教育科、临床技能培训中心）、肿瘤预防研究科。

 

更新日期：2025年10月31日

加载更多

代表性论著

（注：# 第一作者；* 通讯作者）

  1. Chen YP#, Liu X#, Zhou Q#, Yang KY#, Jin F#, Zhu XD#, Shi M#, Hu GQ#, Hu WH#, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL*, Xie FY*, Sun Y*, Ma J*. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021 Jul 24;398(10297):303-313. (IF 168.9)
  2. Chen YP#, Chan AT, Le QT, Blanchard P, Sun Y*, Ma J*. Nasopharyngeal carcinoma. Lancet. 2019; 394(10192): 64-80. (IF 168.9)
  3. Zhang Y#, Chen L#, Hu GQ#, Zhang N#, Zhu XD#, Yang KY#, Jin F#, Shi M#, Chen YP#, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK*, Xie FY*, Sun Y*, Ma J*. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. New England Journal of Medicine. 2019; 381(12): 1124-1135. (IF 158.5)
  4. Lv JW#, Wei Y#, Yin JH#, Chen YP#, Zhou GQ#, Wei C#, Liang XY#, Zhang Y#, Zhang CJ, He SW, He QM, Huang ZL, Guan JL, Shen JY, Li XM, Li JY, Li WF, Tang LL, Mao YP, Guo R, Sun R, Zheng YH, Zhou WW, Xiong KX, Wang SQ, Jin X, Liu N*, Li GB*, Kuang DM*, Sun Y*, Ma J*. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med. 2023 Jun;29(6):1424-1436. (IF 82.9)
  5. Tang LL#, Guo R#, Zhang N, Deng B, Chen L, Cheng ZB, Huang J, Hu WH, Huang SH, Luo WJ, Liang JH, Zheng YM, Zhang F, Mao YP, Li WF, Zhou GQ, Liu X, Chen YP, Xu C, Lin L, Liu Q, Du XJ, Zhang Y, Sun Y*, Ma J*. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA. 2022 Aug 23;328(8):728-736. (IF 120.7)
  6. Mao YP#*, Wang SX#, Gao TS#, Zhang N#, Liang XY#, Xie FY#, Zhang Y, Zhou GQ, Guo R, Luo WJ, Li YJ, Liang SQ, Lin L, Li WF, Liu X, Xu C, Chen YP, Lv JW, Huang SH, Liu LZ, Li JB, Tang LL*, Chen L*, Sun Y*, Ma J*. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. BMJ. 2023 Feb 6;380:e072133. (IF 105.7)
  7. Xu C#, Chen YP#, Du XJ#, Liu JQ#, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J*. Comparative safety of immune checkpoint inhibitors in cancer: a systematic review and network meta-analysis. BMJ. 2018;363:k4226. (IF 105.7)
  8. Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, Wee JTS, Whitley AC, Yi JL, Yom SS, Chan ATC, Hu CS, Lang JY, Le QT, Lee AWM, Lee N, Lin JC, Ma B, Morgan TJ, Shah J, Sun Y*, Ma J*. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021 Mar 1;39(7):840-859. (IF 45.3)
  9. Ma J#*, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY, Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma, J Clin Oncol. 2001; 19(5): 1350-1357. (IF 45.3)
  10. Tang LL#*, Huang CL#, Zhang N#, Jiang W#, Wu YS#, Huang SH, Mao YP, Liu Q, Li JB, Liang SQ, Qin GJ, Hu WH, Sun Y, Xie FY, Chen L*, Zhou GQ*, Ma J*. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022 Apr;23(4):479-490. (IF 51.1)
  11. Tang XR#, Li YQ#, Liang SB#, Jiang W#, Liu F#, Ge WX, Tang LL, Mao YP, He QM, Yang XJ, Zhang Y, Wen X, Zhang J, Wang YQ, Zhang PP, Sun Y, Yun JP, Zeng J, Li L, Liu LZ, Liu N*, Ma J*. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol. 2018;19(3):382-393. (IF 51.1)
  12. Sun Y#, Li WF#, Chen NY#, Zhang N#, Hu GQ#, Xie FY#, Sun Y#, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J*. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016; 17(11):1509-1520. (IF 51.1)
  13. Liu N#, Chen NY#, Cui RX#, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY*, Ma J*. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012; 13(6):633-41. (IF 51.1)
  14. Chen L#, Hu CS#, Chen XZ#, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J*. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012; 13(2):163-71. (IF 51.1)
  15. Chen YP#, Wang YQ#, Lv JW#, Li YQ#, Chua M, Le QT, Lee N, Colevas AD, Seiwert T, Hayes D, Riaz N, Vermorken J, O'Sullivan B, He QM, Yang XJ, Tang LL, Mao YP, Sun Y, Liu N*, Ma J*. Identification and Validation of Novel Microenvironment-based Immune Molecular Subgroups of Head and Neck Squamous Cell Carcinoma: Implications for Immunotherapy. Ann Oncol. 2019;30:68-75. (IF 50.5)
  16. Chen YP#, Wang ZX#, Chen L#, Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J*. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2015; 26(1):205-11. (IF 50.5)
  17. Chen YP#, Yin JH#, Li WF#, Li HJ#, Chen DP#, Zhang CJ#, Lv JW, Wang YQ, Li XM, Li JY, Zhang PP, Li YQ, He QM, Yang XJ, Lei Y, Tang LL, Zhou GQ, Mao YP, Wei C, Xiong KX, Zhang HB, Zhu SD, Hou Y, Sun Y, Dean M, Amit I, Wu K*, Kuang DM*, Li GB*, Liu N*, Ma J*. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 2020 Nov;30(11):1024-1042. (IF 44.1)
  18. Zhang P#, He Q#, Wang Y#, Zhou G, Chen Y, Tang L, Zhang Y, Hong X, Mao Y, He Q, Yang X, Liu N*, Ma J*. Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma. Signal Transduct Target Ther. 2022 Feb 16;7(1):46. (IF 39.3)
  19. Liu N#, He QM#, Chen JW#, Li YQ, Xu YF, Ren XY, Sun Y, Mai HQ, Shao JY, Jia WH, Kang TB, Zeng MS, Ma J*. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth. Mol Cancer. 2014; 13:111. (IF 37.3)
  20. Liu N#, Jiang N#, Guo R#, Jiang W, He QM, Xu YF, Li YQ, Tang LL, Mao YP, Sun Y, Ma J*. MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma. Mol Cancer. 2013; 12(1):123. (IF 37.3)
  21. Chen YP#, Lv JW#, Mao YP#, Li XM#, Li JY#, Wang YQ#, Xu C, Li YQ, He QM, Yang XJ, Lei Y, Shen JY, Tang LL, Chen L, Zhou GQ, Li WF, Du XJ, Guo R, Liu X, Zhang Y, Zeng J, Yun JP, Sun Y*, Liu N*, Ma J*. Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. Mol Cancer. 2021 Jan 11;20(1):14. (IF 37.3)
  22. Liu X#, Zhang Y#, Tang LL#, Le QT, Chua ML, Wee JT, Lee NY, O’Sullivan B, Lee AW, Sun Y, Ma J*. Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. JAMA Oncol. 2018; 4(8): 1073-1079. (IF 28.4)
  23. Liu X#, Chen YP, Li WF, Sun Y, Guo Y, Eisbruch A, Ma J*. Quality of Abstracts Reporting Randomized Clinical Trials Presented at a Major Oncology Conference. JAMA Oncol. 2017; 3(3):414-416. (IF 28.4)
  24. Tang LL#, Li WF, Chen L, Sun Y, Chen Y, Liu LZ, Mao YP, Lin AH, Li L, Ma J*. Prognostic value and staging categories of anatomic masticator space involvement in nasopharyngeal carcinoma: a study of 924 cases with MR imaging. Radiology. 2010; 257(1):151-7. (IF 19.7)
  25. Tang LL#, Chen YP#, Mao YP#, Wang ZX#, Guo R, Chen L, Tian L, Lin AH, Li L, Sun Y, Ma J*. Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma From Endemic Areas in the Intensity-Modulated Radiotherapy Era. J Natl Compr Canc Netw. 2017; 15(7):913-919. (IF 13.4)
  26. Chen YP#, Wang YQ#, Li WF#, Chen L, Xu C, Lu TX, Lin AH, Yao JJ, Li YC, Sun Y, Mao YP, Ma J*. Critical Evaluation of the Quality and Recommendations of Clinical Practice Guidelines for Nasopharyngeal Carcinoma. J Natl Compr Canc Netw. 2017; 15(3):336-344. (IF 13.4)
  27. Chen YP#, Tang LL#, Yang Q#, Poh SS#, Hui EP#, Chan ATC, Ong WS, Tan T, Wee J, Li WF, Chen L, Ma BBY, Tong M, Tan SH, Cheah SL, Fong KW, Sommat K, Soong YL, Guo Y, Lin AH, Sun Y, Hong MH, Cao SM*, Chen MY*, Ma J*. Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. Clin Cancer Res. 2018; 24(8): 1824-1833. (IF 11.5)
  28. Ma J#*, Liu L#, Tang L, Zong J, Lin A, Lu T, Cui N, Cui C, Li L*. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: prognostic value and staging categories. Clin Cancer Res. 2007; 13(5):1445-52. (IF 11.5)
  29. Peng H#, Dong D#, Fang MJ#, Li L#, Tang LL, Chen L, Li WF, Mao YP, Fan W, Liu LZ, Tian L, Lin AH, Sun Y, Tian J*, Ma J*. Prognostic Value of Deep Learning PET/CT-Based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma. Clin Cancer Res. 2019 Jul 15; 25(14): 4271-4279. (IF 11.5)
  30. Zhang J#, Wen X#, Liu N, Li YQ, Tang XR, Wang YQ, He QM, Yang XJ, Zhang PP, Ma J*, Sun Y*. Epigenetic mediated zinc finger protein 671 downregulation promotes cell proliferation and tumorigenicity in nasopharyngeal carcinoma by inhibiting cell cycle arrest. J Exp Clin Cancer Res. 2017; 36(1):147. (IF 12.6)

 

更新日期：2025年6月5日